Seer, Inc. (NASDAQ:SEER) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. reduced its stake in Seer, Inc. (NASDAQ:SEER) by 91.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,867 shares of the company’s stock after selling 203,094 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Seer were worth $35,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SEER. AQR Capital Management LLC purchased a new stake in Seer during the 2nd quarter worth about $30,000. Point72 DIFC Ltd acquired a new position in shares of Seer during the second quarter worth about $35,000. American Century Companies Inc. increased its stake in shares of Seer by 42.1% during the second quarter. American Century Companies Inc. now owns 61,752 shares of the company’s stock worth $104,000 after buying an additional 18,302 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Seer in the second quarter valued at approximately $133,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seer in the second quarter valued at approximately $148,000. 75.20% of the stock is currently owned by hedge funds and other institutional investors.

Seer Stock Down 0.4 %

NASDAQ SEER opened at $2.31 on Friday. Seer, Inc. has a 52 week low of $1.51 and a 52 week high of $2.63. The firm has a 50 day moving average of $2.24 and a two-hundred day moving average of $1.93. The stock has a market capitalization of $136.21 million, a PE ratio of -1.78 and a beta of 1.58.

Seer Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.